{"entity":{"id":"nct07469306","kind":"trial","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","aka":[],"tldr":"A phase 2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine and tislelizumab in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.","summary":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07469306 by Fujian Cancer Hospital, with a registry enrolment figure of 130 participants, started 2026-08-10 and due to reach its primary completion in 2027-08-10. Interventions recorded: Modified Short-course radiotherapy; Long-course radiotherapy; Oxaliplatin; Capecitabine; Tislelizumab; Capecitabine; Tislelizumab. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete Response (CR) Rate. Colorectal eligibility wording from the registry: \"* Pathologically confirmed rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07469306","url":"https://clinicaltrials.gov/study/NCT07469306"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["folfox","capecitabine","tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07469306","phase":"2","setting":"Prospective, Randomized, Phase II Trial of Modified Short-Course Radiotherapy Plus CAPOX and Tislelizumab Versus Long-Course Chemoradiotherapy Plus Tislelizumab for Locally Advanced Rectal Cancer","sponsor":"Fujian Cancer Hospital","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07469306/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}